Tenax Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Tenax Therapeutics, Inc. (NASDAQ: TENX) is a Phase 3, development-stage pharmaceutical company focused on identifying, developing, and commercializing novel cardiopulmonary therapies. The company's primary clinical focus is on its lead product candidate, TNX-103 (oral levosimendan), a first-in-class K-ATP channel activator and calcium sensitizer. TNX-103 is currently being evaluated in late-stage clinical trials for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). This condition represents a massive unmet medical need with no currently approved therapies, positioning TNX-103 as a potential first-in-class oral treatment. Additionally, the company is developing TNX-201 (oral imatinib), a tyrosine kinase inhibitor, as a potential therapy for pulmonary arterial hypertension (PAH).
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Completing the pivotal Phase 3 LEVEL study of TNX-103 (oral levosimendan) targeting pulmonary hypertension with heart failure and preserved ejection fraction (PH-HFpEF).
Expected impact: Establish clinical efficacy and safety of TNX-103 to support future marketing authorization applications.
Advancing the second global, registrational Phase 3 clinical trial (LEVEL-2) of TNX-103 in patients with PH-HFpEF.
Expected impact: Provide the second required pivotal trial dataset for global regulatory submissions.
Prioritizing the development of levosimendan (TNX-103) for pulmonary hypertension and deprioritizing the development of imatinib (TNX-201) for pulmonary arterial hypertension.
Expected impact: Optimize capital allocation and focus clinical development efforts on the highest-probability-of-success asset.